AR067734A1 - Proteina de tipo as160, sistemas de ensayo, y su uso en metodos para la identificacion de terapias para la diabetes de tipo 2 - Google Patents
Proteina de tipo as160, sistemas de ensayo, y su uso en metodos para la identificacion de terapias para la diabetes de tipo 2Info
- Publication number
- AR067734A1 AR067734A1 ARP080103288A ARP080103288A AR067734A1 AR 067734 A1 AR067734 A1 AR 067734A1 AR P080103288 A ARP080103288 A AR P080103288A AR P080103288 A ARP080103288 A AR P080103288A AR 067734 A1 AR067734 A1 AR 067734A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- type
- substance
- cell
- type protein
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 9
- 102000004169 proteins and genes Human genes 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000000126 substance Substances 0.000 abstract 5
- 210000004027 cell Anatomy 0.000 abstract 3
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 abstract 2
- 108091006300 SLC2A4 Proteins 0.000 abstract 2
- 210000000170 cell membrane Anatomy 0.000 abstract 2
- 230000004190 glucose uptake Effects 0.000 abstract 2
- 230000005945 translocation Effects 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000008727 cellular glucose uptake Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07015086A EP2023144A1 (de) | 2007-08-01 | 2007-08-01 | Neues AS160-Protein, Testsysteme, Verfahren und Verwendungen bei der Identifizierung von Therapeutika gegen Typ-2-Diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067734A1 true AR067734A1 (es) | 2009-10-21 |
Family
ID=38702038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103288A AR067734A1 (es) | 2007-08-01 | 2008-07-30 | Proteina de tipo as160, sistemas de ensayo, y su uso en metodos para la identificacion de terapias para la diabetes de tipo 2 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100256014A1 (de) |
| EP (3) | EP2023144A1 (de) |
| JP (1) | JP2010534482A (de) |
| KR (1) | KR20100040740A (de) |
| CN (1) | CN101815943A (de) |
| AR (1) | AR067734A1 (de) |
| AU (1) | AU2008280980B2 (de) |
| BR (1) | BRPI0815378A2 (de) |
| CA (1) | CA2695035A1 (de) |
| IL (3) | IL203532A (de) |
| SG (1) | SG187525A1 (de) |
| TW (1) | TW200923366A (de) |
| WO (1) | WO2009015808A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2219029A1 (de) * | 2009-01-30 | 2010-08-18 | Sanofi-Aventis | Testsysteme, Verfahren und Verwendungen, die AS160-Protein einbeziehen |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
| EP3763419A1 (de) * | 2011-01-07 | 2021-01-13 | Anji Pharma (US) LLC | Auf chemosensorischen rezeptorliganden basierende therapien |
| US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
| NZ626578A (en) | 2012-01-06 | 2016-11-25 | Elcelyx Therapeutics Inc | Compositions and methods for treating metabolic disorders |
| KR102035879B1 (ko) | 2012-01-06 | 2019-10-23 | 엘셀릭스 테라퓨틱스 인코포레이티드 | 바이구아나이드 조성물 및 대사 장애를 치료하는 방법 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Tech | Methoden zur Herstellung humanisierter Antikörper |
| FR2733513B1 (fr) * | 1995-04-25 | 1997-07-18 | Centre Nat Rech Scient | Lignees immortalisees de cellules issues du tissu adipeux humain, leur procede de preparation et leurs applications |
| US7033771B2 (en) * | 2001-05-08 | 2006-04-25 | Takeda Pharmaceutical Company Limited | Use of insulin response modulators in the treatment of diabetes and insulin resistance |
| DE60237917D1 (de) * | 2001-06-05 | 2010-11-18 | Exelixis Inc | Gfats als modifikatoren des p53-wegs und verwendungsverfahren |
| AU2003243532A1 (en) * | 2002-06-10 | 2003-12-22 | Metabolex, Inc. | Methods of treating and diagnosing diabetes with cx3cr1 modulators |
| WO2005019258A2 (en) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US7799538B2 (en) * | 2005-03-09 | 2010-09-21 | Trustees Of Dartmouth College | Method for identifying agents which modulate GTPase activity involved in insulin-stimulated GLUT4 translocation |
-
2007
- 2007-08-01 EP EP07015086A patent/EP2023144A1/de not_active Withdrawn
-
2008
- 2008-07-23 JP JP2010518539A patent/JP2010534482A/ja active Pending
- 2008-07-23 SG SG2013006218A patent/SG187525A1/en unknown
- 2008-07-23 AU AU2008280980A patent/AU2008280980B2/en not_active Ceased
- 2008-07-23 EP EP10185772A patent/EP2302392B1/de active Active
- 2008-07-23 US US12/667,772 patent/US20100256014A1/en not_active Abandoned
- 2008-07-23 KR KR1020107002181A patent/KR20100040740A/ko not_active Application Discontinuation
- 2008-07-23 EP EP08784983.2A patent/EP2176666B1/de active Active
- 2008-07-23 WO PCT/EP2008/006024 patent/WO2009015808A1/en active Application Filing
- 2008-07-23 BR BRPI0815378A patent/BRPI0815378A2/pt not_active IP Right Cessation
- 2008-07-23 CA CA2695035A patent/CA2695035A1/en not_active Abandoned
- 2008-07-23 CN CN200880101474A patent/CN101815943A/zh active Pending
- 2008-07-30 TW TW097128796A patent/TW200923366A/zh unknown
- 2008-07-30 AR ARP080103288A patent/AR067734A1/es not_active Application Discontinuation
-
2010
- 2010-01-26 IL IL203532A patent/IL203532A/en not_active IP Right Cessation
-
2012
- 2012-11-15 IL IL223076A patent/IL223076A0/en unknown
- 2012-11-15 IL IL223077A patent/IL223077A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20100256014A1 (en) | 2010-10-07 |
| AU2008280980A1 (en) | 2009-02-05 |
| EP2176666A1 (de) | 2010-04-21 |
| EP2302392B1 (de) | 2013-01-02 |
| EP2302392A1 (de) | 2011-03-30 |
| WO2009015808A1 (en) | 2009-02-05 |
| TW200923366A (en) | 2009-06-01 |
| CA2695035A1 (en) | 2009-02-05 |
| SG187525A1 (en) | 2013-02-28 |
| EP2023144A1 (de) | 2009-02-11 |
| AU2008280980B2 (en) | 2013-10-31 |
| JP2010534482A (ja) | 2010-11-11 |
| CN101815943A (zh) | 2010-08-25 |
| EP2176666B1 (de) | 2014-02-19 |
| IL223077A0 (en) | 2012-12-31 |
| IL223076A0 (en) | 2012-12-31 |
| BRPI0815378A2 (pt) | 2019-09-24 |
| IL203532A (en) | 2013-09-30 |
| KR20100040740A (ko) | 2010-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067734A1 (es) | Proteina de tipo as160, sistemas de ensayo, y su uso en metodos para la identificacion de terapias para la diabetes de tipo 2 | |
| Shelke et al. | Endosomal signalling via exosome surface TGFβ-1 | |
| ES2570731T3 (es) | Método de detección de cáncer | |
| MX2012004619A (es) | Ensayos regulados mediante proximidad para detectar proteinas de fusion oncogenicas. | |
| CL2017002233A1 (es) | Un factor de coagulación (fvii o fviia) modificado con tres péptidos carboxi terminal de gonadotropina coriónica unidos al carboxi terminal de fvii o fviia; polinucleótido que lo codifica; composición farmacéutica que lo comprende; uso de fvii o fviia modificado para el tratamiento de coagulación de la sangre o un trastorno de coagulación; método para extender la vía media biológica de un factor de coagulación; método para producir dicho fvii o fviia. | |
| Schnellmann et al. | A selective extracellular matrix proteomics approach identifies fibronectin proteolysis by a disintegrin-like and metalloprotease domain with thrombospondin type 1 motifs (ADAMTS16) and its impact on spheroid morphogenesis | |
| PH12015502849A1 (en) | Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers | |
| Hage et al. | The RNA helicase DHX16 recognizes specific viral RNA to trigger RIG-I-dependent innate antiviral immunity | |
| Rubio-Ramos et al. | The MAL protein, an integral component of specialized membranes, in normal cells and cancer | |
| BRPI0710637A2 (pt) | análise do perfil de expressão diferencial de fenótipos de cultura celular e seus usos | |
| Aasebø et al. | The extracellular bone marrow microenvironment—a proteomic comparison of constitutive protein release by in vitro cultured osteoblasts and mesenchymal stem cells | |
| Seitaj et al. | Transmembrane BAX inhibitor-1 motif containing protein 5 (TMBIM5) sustains mitochondrial structure, shape, and function by impacting the mitochondrial protein synthesis machinery | |
| WO2011036666A3 (en) | Systems and methods for measuring translation of target proteins in cells | |
| Eesmaa et al. | CDNF interacts with ER chaperones and requires UPR sensors to promote neuronal survival | |
| WO2008152528A3 (en) | Method for the diagnosis or the screening of an arbovirus infection, reagents useful in said method and their applications | |
| Xue et al. | Hydrogen sulfide improves angiogenesis by regulating the transcription of pri-miR-126 in diabetic endothelial cells | |
| Parekh et al. | Activation of kinin B1R upregulates ADAM17 and results in ACE2 shedding in neurons | |
| Pagesy et al. | Short O-GlcNAcase is targeted to the mitochondria and regulates mitochondrial reactive oxygen species level | |
| Sardar et al. | Mapping astrocyte transcriptional signatures in response to neuroactive compounds | |
| Atkinson et al. | TRIM25 and DEAD-Box RNA helicase DDX3X cooperate to regulate RIG-I-mediated antiviral immunity | |
| Jangphattananont et al. | Distinct localization of mature HGF from its precursor form in developing and repairing the stomach | |
| Cattelani et al. | The SZT2 interactome unravels new functions of the KICSTOR complex | |
| Margiotta | All good things must end: termination of receptor tyrosine kinase signal | |
| WO2013179062A3 (en) | Assays | |
| Zhang et al. | RSPO2 enriches LGR5+ spheroid colon cancer stem cells and promotes its metastasis by epithelial-mesenchymal transition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |